Literature DB >> 11729371

Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction.

I Chern1, A Sharma, D Dennis.   

Abstract

A 61-year-old male with a history of severe heparin-induced thrombocytopenia (HIT) type II after aorto-femoral bypass surgery presented to the emergency department within 8 hours of development of substernal chest pain radiating to the left arm. Electrocardiogram (ECG) on arrival and at 3 hours showed no acute changes; cardiac enzymes revealed minimal MB elevation. Echocardiogram showed normal left ventricular systolic function with mild mitral and tricuspid regurgitation and trace aortic insufficiency. Five hours after arrival, the patient reported a recurrence of severe chest pain. ECG showed marked ST elevations consistent with acute myocardial infarction. Reteplase was administered with concomitant lepirudin. Follow-up ECG showed improvement in ST-segment elevation and eventual resolution to pre-event tracing; cardiac enzymes showed slight elevations. Catheterization revealed 90% midstenosis of the left anterior descending artery, which was successfully treated with percutaneous transluminal coronary angioplasty (PTCA) and stent placement. Repeat PTCA was performed 10 days postdischarge due to intraluminal stent occlusion. The patient was doing well at 6 months follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11729371     DOI: 10.1023/a:1012931707016

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  31 in total

Review 1.  The mechanism of action of thrombin inhibitors.

Authors:  S M Bates; J I Weitz
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

Review 2.  Recombinant hirudin in clinical practice: focus on lepirudin.

Authors:  A Greinacher; N Lubenow
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

3.  Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

Authors:  A Greinacher; U Janssens; G Berg; M Böck; H Kwasny; B Kemkes-Matthes; P Eichler; H Völpel; B Pötzsch; M Luz
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients.

Authors:  A Koster; R Hansen; H Kuppe; R Hetzer; G J Crystal; F Mertzlufft
Journal:  J Cardiothorac Vasc Anesth       Date:  2000-06       Impact factor: 2.628

Review 5.  Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a review.

Authors:  F Fabris; S Ahmad; G Cella; W P Jeske; J M Walenga; J Fareed
Journal:  Arch Pathol Lab Med       Date:  2000-11       Impact factor: 5.534

6.  Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.

Authors:  H D White; P E Aylward; M J Frey; A A Adgey; R Nair; W S Hillis; Y Shalev; M A Brown; J K French; R Collins; J Maraganore; B Adelman
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

8.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

9.  Heparin-associated thrombocytopenia (HAT)--still a diagnostic and therapeutical problem in clinical practice.

Authors:  S Kleinschmidt; U T Seyfert
Journal:  Angiology       Date:  1995-01       Impact factor: 3.619

10.  Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).

Authors:  K Olbrich; M Wiersbitzky; W Wacke; P Eichler; H Zinke; M Schwock; B Möx; G Kraatz; W Motz; A Greinacher
Journal:  Blood Coagul Fibrinolysis       Date:  1998-04       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.